Skip to main content

Table 1 Characteristics of included clinical trials

From: Natriuretic peptide-directed medical therapy: a systematic review

Clinical trialPatientsIntervention arm (n) vs standard care arm (n)†Follow-up (months)
Murdoch et al. (1999)Stable CHF, LVEF ≤ 35%BNP arm n = 10
Standard care n = 10
2
Troughton et al. (2000)Decompensated HF now stabilised, LVEF< 40%BNP arm n = 33
Standard care n = 36
9.5
Beck-da-Silva et al. (2005)> 18 years, stable CHF but not on β blockers, LVEF ≤ 40%BNP arm n = 21
Standard care n = 20
3
Jourdain et al. (2007)> 18 years, optimized on treatment, LVEF < 45%BNP arm n = 110
Standard care n = 110
15
Ozkara et al. (2007)Treated with ACEI/loop diuretic, LVEF ≤ 50%NT-proBNP arm n = 79‡
Standard care n = 61
6
Pfisterer et al. (2009)≥ 60 years, LVEF≤v45%, 60–74 years=NT-proBNP ≥ 400 pg/ml; ≥ 75years = NT-proBNP 800 pg/mlNT-proBNP arm n = 251
Standard care n = 248
18
Lainchbury et al. (2009)*> 18 years, AHF now stabilisedNT-proBNP arm n = 121
Standard care n = 122
36
Anguita et al. (2010)> 18 years, AHFBNP arm n = 30
Standard care n = 30
18
Persson et al. (2010)LVEF < 50%, males NT-proBNP > 800 ng/ml, females> 1000 ng/mlNT-proBNP arm n = 125
Standard care n = 127
9
Eurlings et al. (2010)AHF NT-proBNP > 1700, randomized at discharge if > 10% drop in NT-proBNPNT-proBNP arm n = 174
Standard care n = 171
24
Berger et al. (2010)*AHF now stabilised, LVEF < 40%NT-proBNP + MC arm (only patients with NT-proBNP > 2200 pg/ml) n = 92
Standard care n = 90
Maximum 18; minimum 12
Januzzi Jr et al. (2011)> 21 years, LVEF < 40%NT-proBNP arm n = 75
Standard care n = 76
10
Shah et al. (2011)Decompensation HF now stabilized, LVEF ≤ 35%BNP arm n = 68
Standard care n = 69
4
Karlstrom (2011)> 18 years; BNP > 150 ng/L for those aged < 75 years, and BNP > 300 ng/L for those aged > 75 yearsBNP arm n = 147
Standard care n = 132
33
Maeder et al. (2013)≥ 60 years, LVEF > 45%, 60–74 years = NT-proBNP ≥ 400 pg/ml; ≥ 75 years = NT-proBNP 800pg/mlNT-proBNP arm n = 59
Standard care n = 64
18
Schou et al. (2013)> 18years, Optimised on treatment and implantable ICD/CRT, LVEF < 45%, NT-proBNP > 1000NT-proBNP arm n = 199
Standard care n = 208
Median 30
Carubelli et al. (2016)Randomized after stabilization of AHFNT-proBNP arm n = 137
Standard care n = 134
Mean 18
Stienen et al. (2018)Decompensated HF, NT-proBNP levels > 1700 ng/ml within 24 h of hospital admission. In hospital interventionNT-proBNP arm n = 201
Standard care n = 203
6
Felker et al. (2017)LVEF ≤ 40%, NT-proBNP > 2000 pg/mL/BNP >  400 pg/mlNT-proBNP arm n = 446
Standard care n = 448
12
  1. CHF chronic heart failure, AHF-acute heart failure, NT-proBNP N-terminal pro b-type natriuretic peptide, LVEF left ventricular ejection fraction, ARB angiotensin II receptor blocker, ACEI angiotensin converting enzyme inhibitor, ARA aldosterone receptor antagonist, B-blocker beta blocker, ICD/CRT implantable converter defibrillator/cardiac resynchronisation therapy, BNP B-type natriuretic peptide, MC multidisciplinary care, NYHA New York Heart Association, HF heart failure
  2. †Check Additional file 1
  3. *Randomised to three-arm but only 2 meet the inclusion criteria for this review, NP-directed arm and control arm most reflecting usual patient care
  4. ‡ Only patients in the intervention arm received spironolactone